A citation-based method for searching scientific literature

Geoff Macintyre, Teodora E Goranova, Dilrini De Silva, Darren Ennis, Anna M Piskorz, Matthew Eldridge, Daoud Sie, Liz-Anne Lewsley, Aishah Hanif, Cheryl Wilson, Suzanne Dowson, Rosalind M Glasspool, Michelle Lockley, Elly Brockbank, Ana Montes, Axel Walther, Sudha Sundar, Richard Edmondson, Geoff D Hall, Andrew Clamp, Charlie Gourley, Marcia Hall, Christina Fotopoulou, Hani Gabra, James Paul, Anna Supernat, David Millan, Aoisha Hoyle, Gareth Bryson, Craig Nourse, Laura Mincarelli, Luis Navarro Sanchez, Bauke Ylstra, Mercedes Jimenez-Linan, Luiza Moore, Oliver Hofmann, Florian Markowetz, Iain A McNeish, James D Brenton. Nat Genet 2018
Times Cited: 116



Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke, Charlie Gourley, Susana Banerjee, Amit Oza, Antonio González-Martín, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, Elizabeth S Lowe, Ralph Bloomfield, Paul DiSilvestro. N Engl J Med 2018
Times Cited: 807




List of shared articles



Times cited

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Ionut-Gabriel Funingana, Marika A V Reinius, Angelica Petrillo, Joo Ern Ang, James D Brenton. Semin Cancer Biol 2021
1

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
10

Synthetic Lethality in Ovarian Cancer.
Akshaya Chandrasekaran, Kevin M Elias. Mol Cancer Ther 2021
0

Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Cécile Le Page, Jacqueline Chung, Kurosh Rahimi, Martin Köbel, Diane Provencher, Anne-Marie Mes-Masson. Curr Drug Targets 2020
0

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.
Louisa Nelson, Anthony Tighe, Anya Golder, Samantha Littler, Bjorn Bakker, Daniela Moralli, Syed Murtuza Baker, Ian J Donaldson, Diana C J Spierings, René Wardenaar,[...]. Nat Commun 2020
24

HRness in Breast and Ovarian Cancers.
Elizabeth Santana Dos Santos, François Lallemand, Ambre Petitalot, Sandrine M Caputo, Etienne Rouleau. Int J Mol Sci 2020
5

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R E Miller, A Leary, C L Scott, V Serra, C J Lord, D Bowtell, D K Chang, D W Garsed, J Jonkers, J A Ledermann,[...]. Ann Oncol 2020
36

Clinical assays for assessment of homologous recombination DNA repair deficiency.
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Joyce F Liu. Gynecol Oncol 2020
9

High-throughput approaches for precision medicine in high-grade serous ovarian cancer.
Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q Bernardini, Thomas Kislinger. J Hematol Oncol 2020
6

Insight updating of the molecular hallmarks in ovarian carcinoma.
Alba Mota, Sara S Oltra, Gema Moreno-Bueno. EJC Suppl 2020
1


Epithelial ovarian cancer.
Stephanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M Oza. Lancet 2019
349

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Alejandro Athie, Sara Arce-Gallego, Macarena Gonzalez, Rafael Morales-Barrera, Cristina Suarez, Teresa Casals Galobart, Gonzalo Hernandez Viedma, Joan Carles, Joaquin Mateo. Curr Oncol Rep 2019
11

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
240

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.
Roxane Mari, Emilie Mamessier, Eric Lambaudie, Magali Provansal, Daniel Birnbaum, François Bertucci, Renaud Sabatier. Cancers (Basel) 2019
9